| Dr Susan Renee Clanzy, MD | |
|
310 N Eutaw St, Baltimore, MD 21201-1807 | |
| (410) 446-2257 | |
| Not Available |
| Full Name | Dr Susan Renee Clanzy |
|---|---|
| Gender | Female |
| Speciality | General Practice |
| Location | 310 N Eutaw St, Baltimore, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568435634 | NPI | - | NPPES |
| 3364208 00 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | D0060902 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Susan Renee Clanzy, MD 310 N Eutaw St, Suite 3307, Baltimore, MD 21201-1807 Ph: (410) 446-2257 | Dr Susan Renee Clanzy, MD 310 N Eutaw St, Baltimore, MD 21201-1807 Ph: (410) 446-2257 |
News Archive
Kensey Nash Corporation , a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its first quarter ended September 30, 2010.
Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
MARIJUANA, INC. is proud to announce a corporate name change to Hemp, Inc. The change goes into effect immediately.
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has received U.S. Food and Drug Administration (FDA) approval for meropenem for injection, USP (I.V.) 500 mg and 1 g vials. The medication, a carbapenem that belongs to the beta-lactam class of antibiotics, is a generic version of AstraZeneca's Merrem® I.V. Sales of the name-brand product in the United States were approximately $200 million in 2009.
Investigators at the Massachusetts General Hospital (MGH) Cancer Center have identified a new genetic signature associated with bile duct cancer, a usually deadly tumor for which effective treatment currently is limited.
› Verified 8 days ago
Dr. Jamshid Danaie, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St, Baltimore, MD 21287 Phone: 410-955-9441 | |
Dr. Dara Dane, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 7131 Liberty Rd, Suite 203, Baltimore, MD 21207 Phone: 410-298-1515 Fax: 410-298-9780 | |
King Pascual, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 615 N Wolfe St, Baltimore, MD 21205 Phone: 956-739-8037 | |
Walid Khalid Abu Saleh, MBBS General Practice Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-7399 | |
Maya Das, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 660 W Redwood St, Baltimore, MD 21201 Phone: 410-706-5422 | |
Luigi Ferrucci, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 3001 S Hanover St, 5th Floor, Baltimore, MD 21225 Phone: 410-350-3936 | |
Dr. Khalida Saeed Malik, MD General Practice Medicare: Medicare Enrolled Practice Location: 4167 Patterson Ave, Baltimore, MD 21215 Phone: 410-764-2111 Fax: 410-764-9947 |